Rethinking Recurrence: PIK3CA Mutations in HR+, HER2- Breast Cancer

Early-stage breast cancer patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) tumors face a big challenge: disease recurrence. This kind of cancer is diverse and tricky to manage because a quarter of these patients will see their disease come back, even with treatment. One gene that's often mutated in these cancers is PIK3CA. These mutations make cells grow and multiply too much, which is linked to a worse outcome in advanced breast cancer cases. In Croatia, a real-world study aimed to find out if PIK3CA mutations could also predict how long patients stay disease-free after getting hormonal therapy for early breast cancer. The goal was to see if knowing about these mutations could help doctors plan better treatments tailored to each patient.

PIK3CA mutations are quite common, appearing in 30-40% of advanced HR+/HER2- breast cancer cases. They activate a pathway that helps cells grow and multiply, which isn't good for cancer patients. So, understanding how these mutations affect disease-free survival (DFS) in early breast cancer patients receiving hormonal therapy is important. It could help doctors better support patients and improve their chances of staying disease-free.

Actions